ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies.

Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC. · 2022

Read ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. by Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9644639.txt.

Introduction

Raulin and co-authors review ApoE in Alzheimer's disease, from its disease paths to therapy plans. Alzheimer's is the top cause of dementia in the world. The APOE gene is its strongest genetic risk factor. It bears on more than half of all cases.

One gene form, the ε4 allele, raises risk sharply. The ε2 allele guards against the disease by contrast. The three forms differ at just two amino acid spots. ApoE hauls lipids in the brain and body as its day job. The harmful form seeds amyloid plaques early and thick. Isoforms also split on tau, inflammation, and vessel health. That rich biology makes drug design hard, the authors say. Therapy plans span level tuning and shape fixing drugs. Gene therapy and microRNA routes join the list. New tools for cell type work close the survey.

Catalog record

CREATORRaulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE156 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9644639

Browse the full library · About the Tower of Babel